---
title: The Efficacy and Safety of Short Term S-ketamine Infusion as an Adjunctive Therapy in Patients With Fibromyalgia
nct_id: NCT07230171
overall_status: RECRUITING
phase: NA
sponsor: Beijing Tiantan Hospital
study_type: INTERVENTIONAL
primary_condition: Fibromyalgia
countries: China
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT07230171.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT07230171"
ct_last_update_post_date: 2026-05-07
last_seen_at: "2026-05-12T06:34:53.185Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# The Efficacy and Safety of Short Term S-ketamine Infusion as an Adjunctive Therapy in Patients With Fibromyalgia

**Official Title:** Comparing the Efficacy and Safety of Conventional Therapy With Conventional Therapy Combined Esketamine in the Treatment of Fibromyalgia: A Multicenter Clinical Study

**NCT ID:** [NCT07230171](https://clinicaltrials.gov/study/NCT07230171)

## Key Facts

- **Status:** RECRUITING
- **Phase:** NA
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 92
- **Lead Sponsor:** Beijing Tiantan Hospital
- **Collaborators:** Beijing Ditan Hospital, Beijing Sanbo Brain Hospital
- **Conditions:** Fibromyalgia, Pregabalin, Esketamine
- **Start Date:** 2025-09-15
- **Completion Date:** 2027-08-31
- **CT.gov Last Update:** 2026-05-07

## Brief Summary

Fibromyalgia is a chronic pain syndrome where current medications have limited efficacy and a slow onset of action. Esketamine shows potential as a rapid-acting analgesic, but previous low-dose studies failed to demonstrate long-term benefits. The efficacy of higher-dose ESK as an adjunctive therapy when standard treatments are insufficient remains unclear.

## Eligibility

- **Minimum age:** 18 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria:

* Patients between ages over 18 years with proper cognitive function and language skills for the study;
* Patients diagnosed with FM as defined by the ACR FM diagnostic criteria;
* Patients who have experienced insufficient symptom relief with non-pharmacological treatments and have not previously received recommended pharmacological treatment for FM;
* A score of ≥ 4 on the average pain intensity over 7 days on the numeric rating scale (NRS) at baseline.

Exclusion criteria:

* Patient refusal;
* Inability to sign informed consent;
* Had other secondary FM, this is, hypothyroidism, nutritional deficiency, diabetes mellitus, connective tissue disorder;
* Had psychiatric disorder, this is, schizophrenia and other psychotic disorder, bipolar disorder, or personality disorder;
* Obstructive sleep apnea syndrome or a STOP-Bang score ≥ 3;
* History of treatment with pregabalin and/or venlafaxine for any disease;
* History of treatment with intravenous ketamine or ESK for chronic pain;
* Presence of other painful ailments such as inflammatory rheumatic disease;
* Uncontrolled diabetes, refractory hypertension, malignancies, narrow-angle glaucoma, hyperthyroidism, severe cardiovascular disease or any other contraindications to esketamine;
* History of prescription drug abuse, alcoholism or illicit drug use;
* Pregnant or lactating women;
* Allergic to any of the study drugs.
```

## Arms

- **Control group** (ACTIVE_COMPARATOR) — Pregabalin and venlafaxine concomitant therapy
- **Treatment group** (EXPERIMENTAL) — Esketamine plus pregabalin and venlafaxine concomitant therapy

## Interventions

- **Pregabalin and venlafaxine concomitant therapy** (DRUG) — The control group will only receive an increased dosage of pregabalin and venlafaxine regimen. Each participant will be instructed with the same dose escalation regimen, until they reach the maximal tolerated dose (MTD) or the ceiling dose or the maximum daily recommended dose. The maximum recommended daily dose of pregabalin was 450 mg and venlafaxine was 225 mg.
- **Esketamine plus pregabalin and venlafaxine concomitant therapy** (DRUG) — The treatment group, in addition to the increased pregabalin and venlafaxine medication dosage regimen, will also receive a single intravenous infusion of esketamine on the day of enrollment. Plasma concentrations of esketamine and its metabolites will be measured at the end of infusion to enable a limited characterization of systemic exposure and to support exploratory exposure-response analyses. Each participant will be instructed with the same dose escalation regimen, until they reach the maximal tolerated dose (MTD) or the ceiling dose or the maximum daily recommended dose. The maximum recommended daily dose of pregabalin was 450 mg and venlafaxine was 225 mg.

## Primary Outcomes

- **Change from baseline in the mean pain intensity** _(time frame: At the week 1.)_ — This outcome is calculated as the average of daily 24-hour pain intensity scores recorded in patient diaries over 7 consecutive days using NRS.

## Secondary Outcomes

- **Average pain intensity** _(time frame: At the weeks 1, 2, 4, 8, and 12)_
- **Worst pain intensity** _(time frame: at weeks 1, 2, 4, 8, and 12)_
- **Proportion of patients achieving pain reduction at 50% and 30%;** _(time frame: at weeks 1, 2, 4, 8, and 12)_
- **The median pain relief time** _(time frame: Through study completion, an average of 12 weeks)_
- **The maximal tolerated doses of pregabalin and venlafaxine** _(time frame: at weeks 1, 2, 4, 8, and 12)_
- **The Revised FM Impact Questionnaire (FIQR)** _(time frame: At the weeks 4, 8, and 12)_
- **Hospital Anxiety and Depression scale (HADS)** _(time frame: At the weeks 4, 8, and 12)_
- **The short-form 36 Health Survey (SF-36)** _(time frame: At the weeks 4, 8, and 12)_
- **Multidimensional Fatigue Inventory (MFI)** _(time frame: At the weeks 4, 8, and 12)_
- **Medical Outcomes Study Sleep Scale (MOS)** _(time frame: At the weeks 4, 8, and 12)_
- **Plasma concentrations of esketamine and its metabolites at the end of infusion** _(time frame: At the end of esketamine infusion, that is at day 0)_
- **Adverse events** _(time frame: Through study completion, an average of 12 weeks)_

## Locations (1)

- Beijing Tiantan Hospital, Beijing, Beijing 100070, Beijing, China — _RECRUITING_

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `sponsor.collaborators` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.beijing tiantan hospital, beijing, beijing 100070|beijing||china` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT07230171.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT07230171*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*